Form 4: Nuvalent CEO Sells Shares, Acquires New Equity Awards

Nuvalent's President and CEO, James Richard Porter, reported sales of Class A Common Stock under a 10b5-1 plan for tax obligations, alongside the acquisition of new restricted stock units and stock options.

Summary

• James Richard Porter, President and CEO of Nuvalent, Inc., reported multiple transactions involving the company's Class A Common Stock.
• A total of 27,433 shares of Class A Common Stock were disposed of through sales on January 5, 2026, and January 6, 2026.
• The sales were executed at weighted average prices ranging from $96.06 to $98.52 per share.
• These sales were conducted pursuant to a Rule 10b5-1 sell-to-cover instruction letter, established on December 6, 2023, to satisfy tax withholding obligations upon the vesting of previously granted equity awards.
• Porter acquired 46,250 shares of Class A Common Stock through restricted stock units (RSUs) on January 7, 2026, at a price of $0.00.
• These RSUs are scheduled to vest in three equal annual installments following January 7, 2026, contingent on continued service to Nuvalent, Inc.
• Additionally, Porter acquired 46,250 stock options on January 7, 2026, with an exercise price of $106.82 and a price of $0.00.
• The stock options will vest over four years following January 7, 2026, in equal monthly installments, also subject to continued service.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions, including sales for tax obligations under a pre-arranged plan and the acquisition of new equity awards, indicating continued long-term incentive alignment. This is generally neutral to slightly positive.

Positives

• The acquisition of 46,250 restricted stock units and 46,250 stock options indicates continued long-term incentive alignment between the CEO and shareholder interests.
• The vesting schedules for the new equity awards (RSUs over three years, options over four years) suggest a commitment to the company's future performance.

Negatives

• The sale of 27,433 shares by a key executive, even for tax purposes, represents a reduction in direct beneficial ownership, which some investors might view with caution.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on insider transactions.

Management Comments

• The sales were effected pursuant to a durable Rule 10b5-1 sell-to-cover instruction letter entered into on December 6, 2023, to satisfy the reporting person's tax withholding obligations upon the vesting of previously granted equity awards.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity and does not provide information directly related to broader industry trends or competitive landscape. It reflects standard executive compensation practices within the biotechnology or pharmaceutical sector, where equity awards are a common component.

Stakeholder Impact

• Shareholders: May view the sales as routine for tax purposes and the new equity awards as a positive sign of continued management commitment and alignment with long-term company performance.
• Employees: No direct impact mentioned, but the CEO's continued equity awards reinforce leadership's stake in the company's future.

Next Steps

• Vesting of 46,250 restricted stock units in three equal annual installments following January 7, 2026.
• Vesting of 46,250 stock options over four years in equal monthly installments following January 7, 2026.

Key Dates

Recommendation

This Form 4 details routine insider transactions, specifically sales by the CEO to cover tax obligations from vested equity awards, alongside the grant of new restricted stock units and stock options. These actions are common and generally do not signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. Investors should continue to evaluate Nuvalent based on its operational performance, clinical pipeline, and broader market conditions.

Keywords

Nuvalent, NUVL, Insider Transaction, Form 4, Stock Sale, Equity Awards, CEO, Restricted Stock Units, Stock Options, 10b5-1 Plan